Artikel ; Online: Circadian regulation of MGMT expression and promoter methylation underlies daily rhythms in TMZ sensitivity in glioblastoma.
2024 Band 166, Heft 3, Seite(n) 419–430
Abstract: Background: Glioblastoma (GBM) is the most common primary brain tumor in adults. Despite extensive research and clinical trials, median survival post-treatment remains at 15 months. Thus, all opportunities to optimize current treatments and improve ... ...
Abstract | Background: Glioblastoma (GBM) is the most common primary brain tumor in adults. Despite extensive research and clinical trials, median survival post-treatment remains at 15 months. Thus, all opportunities to optimize current treatments and improve patient outcomes should be considered. A recent retrospective clinical study found that taking TMZ in the morning compared to the evening was associated with a 6-month increase in median survival in patients with MGMT-methylated GBM. Here, we hypothesized that TMZ efficacy depends on time-of-day and O Methods and results: In vitro recordings using real-time bioluminescence reporters revealed that GBM cells have intrinsic circadian rhythms in the expression of the core circadian clock genes Bmal1 and Per2, as well as in the DNA repair enzyme, MGMT. Independent measures of MGMT transcript levels and promoter methylation also showed daily rhythms intrinsic to GBM cells. These cells were more susceptible to TMZ when delivered at the daily peak of Bmal1 transcription. We found that in vivo morning administration of TMZ also decreased tumor size and increased body weight compared to evening drug delivery in mice bearing GBM xenografts. Finally, inhibition of MGMT activity with O Conclusion: We conclude that chemotherapy with TMZ can be dramatically enhanced by delivering at the daily maximum of tumor Bmal1 expression and minimum of MGMT activity and that scoring MGMT methylation status requires controlling for time of day of biopsy. |
---|---|
Mesh-Begriff(e) | Humans ; Animals ; Mice ; Glioblastoma/drug therapy ; Glioblastoma/genetics ; Glioblastoma/pathology ; Temozolomide/pharmacology ; Temozolomide/therapeutic use ; Dacarbazine/therapeutic use ; Antineoplastic Agents, Alkylating/pharmacology ; Antineoplastic Agents, Alkylating/therapeutic use ; O(6)-Methylguanine-DNA Methyltransferase/genetics ; Retrospective Studies ; ARNTL Transcription Factors/genetics ; ARNTL Transcription Factors/metabolism ; Methylation ; DNA Repair Enzymes/genetics ; DNA Repair Enzymes/metabolism ; DNA Modification Methylases/genetics ; DNA Modification Methylases/metabolism ; DNA Methylation ; Brain Neoplasms/drug therapy ; Brain Neoplasms/genetics ; Brain Neoplasms/pathology ; Tumor Suppressor Proteins/genetics ; Tumor Suppressor Proteins/metabolism |
Chemische Substanzen | Temozolomide (YF1K15M17Y) ; Dacarbazine (7GR28W0FJI) ; Antineoplastic Agents, Alkylating ; O(6)-Methylguanine-DNA Methyltransferase (EC 2.1.1.63) ; ARNTL Transcription Factors ; DNA Repair Enzymes (EC 6.5.1.-) ; DNA Modification Methylases (EC 2.1.1.-) ; MGMT protein, human (EC 2.1.1.63) ; Tumor Suppressor Proteins |
Sprache | Englisch |
Erscheinungsdatum | 2024-01-26 |
Erscheinungsland | United States |
Dokumenttyp | Journal Article |
ZDB-ID | 604875-4 |
ISSN | 1573-7373 ; 0167-594X |
ISSN (online) | 1573-7373 |
ISSN | 0167-594X |
DOI | 10.1007/s11060-023-04535-9 |
Datenquelle | MEDical Literature Analysis and Retrieval System OnLINE |
Volltext online
Zusatzmaterialien
Kategorien
Verfügbar in ZB MED Köln/Königswinter
Zs.A 1825: Hefte anzeigen | Standort: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.